Compare
Up to five products, technologies, targets, trials, or cancers side by side, same fields, differences highlighted. The URL is shareable.
Up to five products, technologies, targets, trials, or cancers side by side, same fields, differences highlighted. The URL is shareable.
| Field | ProductApproved Sacituzumab govitecan The first TROP2-targeted ADC. It delivers a strong chemotherapy directly to breast and bladder cancer cells and is now a first-line option in triple-negative breast cancer. | ProductApproved Datopotamab deruxtecan Datopotamab deruxtecan (Datroway) is the second TROP2 ADC and shares Enhertu's payload. In 2026 it became a first-line option for triple-negative breast cancer patients who cannot receive immunotherapy. | ProductPhase 3 Sacituzumab tirumotecan Sacituzumab tirumotecan is a third TROP2 ADC from China, licensed to Merck for a very large global programme. It is approved in China; in the US it has a priority voucher but not yet approval. |
|---|---|---|---|
| Brand / code• | Trodelvy · IMMU-132 | Datroway · Dato-DXd, DS-1062 | sac-TMT, MK-2870, SKB264 |
| Modality | ADC | ADC | ADC |
| Mechanism• | Humanised anti-TROP2 IgG1 (hRS7) internalised; SN-38 released by linker hydrolysis inside and around tumour cells. | Humanised anti-TROP2 IgG1 with DXd; internalisation, lysosomal release, TOP1 inhibition, bystander effect. | Anti-TROP2 IgG1 with a stable, irreversibly-conjugated linker and a belotecan-derived TOP1 payload with reported lower efflux-pump susceptibility. |
| Payload• | SN-38 (topoisomerase-I inhibitor), DAR ~7.6 | DXd (TOP1 inhibitor), DAR ~4 | T030 (belotecan-derived TOP1 inhibitor), DAR ~7.4 |
| Linker• | CL2A, pH-sensitive cleavable | Tetrapeptide GGFG, cleavable | Sulfonyl pyrimidine (CL2A-like), pH-sensitive and enzyme-cleavable |
| Targets | TROP2 | TROP2 | TROP2 |
| Cancers• | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, Bladder & urothelial cancer | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer | Triple-negative breast cancer (TNBC), Non-small-cell lung cancer, HR-positive / HER2-negative breast cancer, Endometrial cancer, Cervical cancer |
| Companies• | Gilead Sciences (incl. Kite) | Daiichi Sankyo, AstraZeneca | Sichuan Kelun-Biotech, Merck & Co. (MSD) |
| First approval• | 2020 | 2025 | 2024 |
| Approvals• | US 2020: Metastatic TNBC, ≥2 prior lines (accelerated; full 2021) · US 2023: HR+/HER2- metastatic breast cancer after endocrine therapy and ≥2 chemotherapies · US 2026: First-line metastatic TNBC: monotherapy (PD-1 ineligible) or with pembrolizumab (PD-L1 CPS ≥10) | US 2025: HR+/HER2- metastatic breast cancer after endocrine therapy and chemotherapy · US 2025: EGFR-mutant NSCLC after EGFR TKI and platinum chemotherapy · US 2026: First-line unresectable/metastatic TNBC, PD-1/PD-L1 inhibitor ineligible | China 2024: Pretreated advanced TNBC; later EGFR-mutant NSCLC after TKI |
| Dosing• | IV infusion; 10 mg/kg on days 1 and 8 of each 21-day cycle; monitor: Blood counts each dose; UGT1A1*28 homozygotes have earlier and more frequent neutropenia; anti-emetic premedication | IV infusion; 6 mg/kg (maximum 540 mg for ≥90 kg) every 3 weeks; monitor: Oral care with steroid mouthwash prophylaxis; baseline and periodic eye examination; respiratory symptoms | IV infusion; 5 mg/kg every 2 weeks (China label, TNBC); phase 3 trials use 4 mg/kg every 2 weeks in combination regimens; monitor: Blood counts; stomatitis and ocular surface care |
| Grade ≥3 toxicities• | Neutropenia 49% · Anaemia 9% · Fatigue 6% · Diarrhoea 11% · Nausea 3.1% · Alopecia 0% · Constipation 0.4% · Vomiting 1.6% · Decreased appetite 1.6% · Rash 0.4% | Stomatitis 7% · Nausea 1.4% · Fatigue 4.2% · Alopecia 0% · Constipation 0.3% · Dry eye 0.8% · Keratitis 1.1% · Vomiting 1.1% | — |
| Access• | US: Medicare Part B (physician-administered); commercial plans per formulary · UK: NICE: recommended for pretreated metastatic TNBC (TA819) and HR+/HER2- breast cancer after endocrine therapy and chemotherapy · EU: EMA approved; national reimbursement varies | US: Medicare Part B (physician-administered); commercial plans per formulary · UK: NICE: appraisal in progress for HR+/HER2- breast cancer; not yet recommended (2026) | CN: NMPA approved 2024; National Reimbursement Drug List inclusion from 2025 · US: Investigational; not yet approved |
| Regulatory events• | 2016-02-05 designation (US) · 2020-04-22 approval (US) · 2021-04-07 approval (US) · 2021-11-22 approval (EU) · 2023-02-03 approval (US) · 2024-11 withdrawal (US) · 2026-Q2 approval (US) | 2025-01-17 approval (US) · 2025-03 approval (JP) · 2025-06-23 approval (US) · 2026-Q2 approval (US) | 2022-05 filing (China) · 2024-11 approval (China) · 2024-12-03 designation (US) · 2025-03 approval (China) · 2026-07 designation (US) |
| Key trials• | ASCENT, ASCENT-03, ASCENT-04 / KEYNOTE-D19 | TROPION-Breast01, TROPION-Breast02, TROPION-Breast05, TROPION-Lung01 | — |
Rows marked • differ between the selected items. Fields come from the OnCo records; empty fields render as —. Add more data to a record on GitHub to fill a gap.